55 reports of this reaction
2.5% of all NELARABINE reports
#5 most reported adverse reaction
SEPSIS is the #5 most commonly reported adverse reaction for NELARABINE, manufactured by Novartis Pharmaceuticals Corporation. There are 55 FDA adverse event reports linking NELARABINE to SEPSIS. This represents approximately 2.5% of all 2,208 adverse event reports for this drug.
Patients taking NELARABINE who experience sepsis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEPSIS is a less commonly reported adverse event for NELARABINE, but still significant enough to appear in the safety profile.
In addition to sepsis, the following adverse reactions have been reported for NELARABINE:
The following drugs have also been linked to sepsis in FDA adverse event reports:
SEPSIS has been reported as an adverse event in 55 FDA reports for NELARABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEPSIS accounts for approximately 2.5% of all adverse event reports for NELARABINE, making it a notable side effect.
If you experience sepsis while taking NELARABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.